Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
2022 full year guidance
Expected, barring unforeseen events; growth vs. PY in cc
Innovative
Medicines
Sales to grow mid single digit
Core Oplnc to grow mid to high single digit, ahead of sales
Sandoz
Group
Sales to grow low to mid single digit (revised upwards from to grow low single digit)
Core Oplnc to grow low single digit (revised upwards from broadly in line)
Sales to grow mid single digit
Core Oplnc to grow mid single digit
Key assumptions
Our guidance assumes that we see a continuing return to normal global healthcare systems, including prescription dynamics,
and that no SandostatinⓇ LAR generics enter in the US.
In June 2022, an appeals court held the Gilenya US dosing regimen patent invalid. Novartis will file a petition seeking further review with the US Supreme
Court, which denied a motion to stay the issuance of the formal appeal mandate while further review is ongoing. FDA-approved Gilenya generics now
launched in the US. In Q3, Gilenya US sales were USD 326 million.
24 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation